Back to Browse Journals » Vascular Health and Risk Management » Volume 5

The management of gestational diabetes

Authors N Wah Cheung

Published 15 January 2009 Volume 2009:5 Pages 153—164

DOI http://dx.doi.org/10.2147/VHRM.S3405

Review by Single-blind

Peer reviewer comments 2

N Wah Cheung

Centre for Diabetes and Endocrinology Research, Westmead Hospital, and University of Sydney, NSW, Australia

Abstract: The incidence of gestational diabetes is increasing. As gestational diabetes is associated with adverse pregnancy outcomes, and has long-term implications for both mother and child, it is important that it is recognized and appropriately managed. This review will examine the pharmacological options for the management of gestational diabetes, as well as the evidence for blood glucose monitoring, dietary and exercise therapy. The medical management of gestational diabetes is still evolving, and recent randomized controlled trials have added considerably to our knowledge in this area. As insulin therapy is effective and safe, it is considered the gold standard of pharmacotherapy for gestational diabetes, against which other treatments have been compared. The current experience is that the short acting insulin analogs lispro and aspart are safe, but there are only limited data to support the use of long acting insulin analogs. There are randomized controlled trials which have demonstrated efficacy of the oral agents glyburide and metformin. Whilst short-term data have not demonstrated adverse effects of glyburide and metformin on the fetus, and they are increasingly being used in pregnancy, there remain long-term concerns regarding their potential for harm.

Keywords: gestational diabetes, insulin, oral antidiabetic agents, pregnancy, type 2 diabetes

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Comparison between oscillometric- and Doppler-ABI in elderly individuals

Takahashi I, Furukawa K, Ohishi W, Takahashi T, Matsumoto M, Fujiwara S

Vascular Health and Risk Management 2013, 9:89-94

Published Date: 8 March 2013

Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment

Lukashevich V, Schweizer A, Foley JE, Dickinson S, Groop PH, Kothny W

Vascular Health and Risk Management 2013, 9:21-28

Published Date: 23 January 2013

Low body temperature associated with severe ischemic stroke within 6 hours of onset: The Bergen NORSTROKE Study

Kvistad CE, Thomassen L, Waje-Andreassen U, Naess H

Vascular Health and Risk Management 2012, 8:333-338

Published Date: 1 June 2012

Angiopoietin-1-expressing adipose stem cells genetically modified with baculovirus nanocomplex: investigation in rat heart with acute infarction

Paul A, Nayan M, Khan AA, Shum-Tim D, Prakash S

International Journal of Nanomedicine 2012, 7:663-682

Published Date: 8 February 2012

The impact of diurnal fasting during Ramadan on the lipid profile, hs-CRP, and serum leptin in stable cardiac patients

Khafaji HARH, Bener A, Osman M, Al Merri A, Al Suwaidi J

Vascular Health and Risk Management 2012, 8:7-14

Published Date: 30 December 2011

Efficacy and safety of tiotropium Respimat® SMI in COPD in two 1-year randomized studies

Eric Bateman, Dave Singh, David Smith, et al

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:197-208

Published Date: 9 June 2010

Should we screen for masked hypertension in patient with vascular disease?

Pascal Delsart, Philippe Marboeuf, Cedric Delhaye, et al

Vascular Health and Risk Management 2010, 6:333-338

Published Date: 10 May 2010

New standards in hypertension and cardiovascular risk management: focus on telmisartan

Domenico Galzerano, Cristina Capogrosso, Sara Di Michele, et al

Vascular Health and Risk Management 2010, 6:113-133

Published Date: 4 March 2010

Low use of statins and other coronary secondary prevention therapies in primary and secondary care in India

Krishna K Sharma, Rajeev Gupta, Aachu Agrawal, et al

Vascular Health and Risk Management 2009, 5:1007-1014

Published Date: 20 November 2009